t its heart, the ongoing legal battle to block US federal funding for research on human embryonic stem (ES) cells seeks to protect embryos.
But Nature has learned that in a bitter irony, the dispute seems to be holding up research on lines of human ES cells that can be derived without destroying embryos. The delay is also hampering work that researchers say could help to make adult cells a viable source of stem cells for therapies in a wide range of diseases.
In 2009, the US National Institutes of Health (NIH) unveiled draft guidelines on the human ES cell work that would be eligible for government funds. But public comments on the draft recommended a more precise definition of the eligible cells. Rather than classing human ES cells as those derived from a human embryo, as the NIH had done originally, the agency was advised to restrict the definition to cells derived from a blastocyst -an embryo of more than 100 cells. In making that change, however, the NIH inadvertently excluded a handful of lines that had been derived from a single cell -a blastomere -plucked from an eight-celled human embryo (pictured). Although deriving stem cells from a blastocyst destroys it, extracting a single blastomere -something routinely done to look for defective genes in embryos intended for in vitro fertilization -seems to do no harm, leaving a viable embryo that can be frozen.
Last year, the NIH proposed a further change to the ES-cell definition that would make lines derived from embryos younger than blastocysts eligible for funding (see Nature doi:10.1038 (see Nature doi:10. /news.2010 2010 the embryos themselves will be frozen rather than destroyed after the procedure.
Some researchers say that the restrictions on US federal support for single-blastomere lines could hamper efforts to explore the potential of stem cells generated from adult tissue. Called induced pluripotent stem (iPS) cells, these were once heralded as a potential replacement for ES cells. But recent findings suggest that they differ in some ways from ES cells (see Nature 470, 13; 2011). How those differences affect pluripotency -the ability to develop into many of the body's cell types -remains unclear. "The ultimate question for the field now is what defines pluripotency, " says Chad Cowan, a stem-cell researcher at Harvard Medical School in Boston.
Early data from Fisher's lab -from studies funded by the California Institute of Regenerative Medicine -suggest that single-blastomere ES cells are even more malleable than those from blastocysts. "Not having federal funds used on cell lines derived from earlier embryos can stifle our opportunity to understand this pluripotent state, " says Cowan.
"Single-blastomere lines are several times more efficient at generating certain replacement cell types than are the dozens of other human embryonic stem-cell lines we've tested, " adds Robert Lanza, chief scientific officer at ACT, which has patented the single-blastomere technique.
For ACT, the funding restrictions also threatened to delay a clinical trial. The company had been counting on funding from the Foundation Fighting Blindness, a non-profit organization based in Columbia, Maryland, to back its trial of a therapy for Stargardt's disease, a hereditary cause of blindness in children. But the human ES cells in the therapy were derived from a blastomere, and as the foundation draws its clinical-trial support from the federally funded National Eye Evaluation Research Network, it was barred from contributing to the costs of the trial. "We're tearing our hair out over here, " says Stephen Rose, chief research officer at the Foundation Fighting Blindness. "We really wanted to help fund this trial. " Eventually, ACT pulled money from its other research programmes to fund the trial, which is scheduled to begin later this year. ■
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Stem cells derived from blastomeres are stuck in regulatory limbo. 
Cell

IN FOCUS NEWS
